文献速递毛发、甲与色素性疾病

托法替布治疗青少年斑秃及变异型

Tofacitinib for the treatment of alopecia areata and variants in adolescents.
PubMed 文献 · J Am Acad Dermatol · 2016-11-02

该回顾性病例系列评估了Janus激酶1/3抑制剂托法替布在13例12至17岁斑秃青少年中的疗效与安全性。9例出现临床显著毛发再生,SALT评分中位变化93%,平均治疗6.5个月,不良反应轻微。结论认为托法替布是青少年斑秃有前景的疗法,需前瞻性临床试验进一步验证。

要点

  • 托法替布在13例青少年斑秃中9例出现临床显著毛发再生。
  • SALT评分中位变化93%,平均治疗6.5个月,不良反应轻微。
  • 证据来自小样本回顾性研究,需前瞻性对照试验确认。

核心结论

  • 托法替布是青少年斑秃有前景的治疗选择。

研究设计与样本

  • 回顾性病例系列,纳入13例12至17岁斑秃青少年,接受托法替布治疗。

主要发现

  • 13例中9例出现临床显著毛发再生。
  • SALT评分中位变化93%(均值61%,范围1%-100%),平均治疗6.5个月。
  • 不良事件均为轻度。

关键数值与推荐

  • 疾病严重度采用SALT工具评估。
  • 不良事件通过实验室监测、体格检查和系统回顾评估。

临床怎么用

  • 在充分告知超说明书用药与监测要求的前提下,可考虑托法替布用于青少年斑秃。
  • 治疗期间应通过SALT评分和实验室监测评估疗效与安全性。

局限性

  • 数据为回顾性。
  • 样本量小。
  • 缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are no reliably effective therapies for alopecia areata (AA). OBJECTIVE: We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA. METHODS: We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems. RESULTS: Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild. LIMITATIONS: Limitations include the retrospective nature of the data, small sample size, and lack of a control group. CONCLUSION: Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Craiglow BG, Liu LY, King BA, et al. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2016. PMID: 27816292. doi:10.1016/j.jaad.2016.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。